{"id":4601,"date":"2024-09-10T14:21:56","date_gmt":"2024-09-10T04:21:56","guid":{"rendered":"\/americas\/?p=4601"},"modified":"2024-09-10T14:21:56","modified_gmt":"2024-09-10T04:21:56","slug":"ausbiz-interview-with-john-van-der-wielen","status":"publish","type":"post","link":"\/americas\/ausbiz-interview-with-john-van-der-wielen\/","title":{"rendered":"Ausbiz | Interview with John Van Der Wielen"},"content":{"rendered":"

Orthocell Chairman, John Van Der Wielen spoke with ausbiz host Nadine Blayney about the Company\u2019s expansion into Canada with dental bone regeneration product, Striate+, and Orthocell\u2019s strong outlook for revenue growth.<\/p>\n

Here\u2019s an excerpt:<\/p>\n

\u201cIn seven quarters, we\u2019ve had 9% CAGR up quarter on quarter, and we don\u2019t expect that to slow down. In fact, we expect it to increase as we bring on new regulatory approvals. And what we’ve just proven with Canada, it was about eight weeks until we got our first sale, so we expect the exponential growth now to speed up.\u201d<\/p>\n

Take a look:
\n